A Single Center, Randomized, Double-blind Controlled Trial of Sitagliptin Versus Placebo to Reduce the Incidence and Severity of New-onset Diabetes After Kidney Transplant
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Jul 2019
Price : $35 *
At a glance
- Drugs Sitagliptin (Primary)
- Indications Diabetes mellitus
- Focus Therapeutic Use
- 12 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 14 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.